Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to determine the proportion of clinical improvement, the score changing of type 1 interferon selected gene expression, and analysis of transcriptomics profiling in patients with idiopathic uveitis positive IGRA before and after receiving Anti-Tuberculosis Therapy (ATT). Hopefully, by conducting this research, we are able to provide valid data that demonstrate the advantages/disadvantages usage of Anti-Tuberculosis Therapy in patients with idiopathic uveitis IGRA positive that correlate with type I IFN. This research is a part of our efforts in discovering bio-marker candidates of idiopathic uveitis IGRA positive clinical patients who will benefit from the ATT administration.


Clinical Trial Description

Diagnostic of Idiopathic Uveitis IGRA Positive patients were still unclear. This situation happens because it is still can't be explained if the uveitis from the patients was caused by mycobacterium tuberculosis or not which leads to doubtfulness for Anti-Tuberculosis Treatment (ATT). This study aims to help to provide evidence on whether ATT usage for Idiopathic Uveitis IGRA Positive would bring beneficial impact for the patients. This study will try to analyze the data from clinical improvements, Type 1 Interferon changes, and transcriptomics analysis from the patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04088019
Study type Observational [Patient Registry]
Source Fakultas Kedokteran Universitas Indonesia
Contact Rina La Distia Nora
Phone +62811-198-910
Email rina.ladistia@ui.ac.id
Status Recruiting
Phase
Start date October 30, 2019
Completion date July 2024

See also
  Status Clinical Trial Phase
Completed NCT03211208 - Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients